

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION NO.	SOURCE(S)	OBJECTION(S)
321	NZ	7/9/02	FNA4 License Agreement	NV-D-0175443 to NV-D-0175455	Exh. 7 to the Julie L. Davis Deposition; Exh. 4 to the	Stipulated
322	NZ	1/2/02	Phytase License Agreement	NV-D-0175456 to NV-D-0175476	Exh. 8 to the Julie L. Davis Deposition; Exh. 7 to the	Stipulated
323	NZ	7/9/02	Settlement Agreement between Genencor International, Inc. and Novozymes A/S	GCOR-171612 to GCOR-171613	Exh. 7 to the Julie L. Davis Deposition; Exh. 4 to the	Stipulated
324	NZ	7/9/02	FNA4 License Agreement between Genencor International, Inc. and Novozymes A/S	GCOR-171614 to GCOR-171626	Exh. 7 to the Julie L. Davis Deposition; Exh. 4 to the	Stipulated
325	NZ	7/9/02	Carezyme License Agreement between Genencor International, Inc. and Novozymes A/S	GCOR-171627 to GCOR-171638	Exh. 7 to the Julie L. Davis Deposition; Exh. 4 to the	Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION NO.	SOURCE(S)	OBJECTION(S)
326	NZ	7/9/02	Kannase License Agreement between Genencor International, Inc. and Novozymes A/S	GCOR-171639 to GCOR-171649		Stipulated
327	NZ	7/9/02	Amylase License Agreement between Genencor International, Inc. and Novozymes A/S	GCOR-171650 to GCOR-171659		Stipulated
328	NZ	3/23/98	Settlement Agreement between Novo Nordisk A/S, Novo Nordisk of N.A., Inc., Novo Nordisk Biochem N.A. and Genencor International, Inc. (with the attached Second Amendment to Filamentous Fungi License Agreement, Release relating to Tolling Agreement, Protease License Agreement, Bacillus License Agreement, DURAMYL License Agreement, Color Clarification License Agreement, and Alpha-Amylase / Gluco-amylase License Agreement)	GCOR-171660 to GCOR-171704		Partial Stipulation; object to portions of collective exhibits. See GCOR TE 733-735

T.E. #.	OFFERED By	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
329	NZ	8/16/96	M222S License Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171705 to GCOR-171713		Partial Stipulation; object to portions of collective exhibits. See portion of TE 735
330	NZ	8/16/96	Aspergillus License Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171714 to GCOR-171720		Stipulated
331	NZ	8/16/96	Tolling Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171721 to GCOR-171726		F.R.E. 401-402
332	NZ	6/28/95	Amendment to Filamentous Fungi License Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171727 to GCOR-171728		Stipulated
333	NZ	6/28/95	Amendment to <i>Trichoderma</i> License Agreement between Novo Nordisk A/S Genencor International, Inc.	GCOR-171729 to GCOR-171730		Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
334	NZ/GCOR	4/3/95	Durazyme License Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171731 to GCOR-171741	Exh. 13 to the Marianne-Weile Nonboe Deposition	Stipulated
335	NZ	4/4/95	Appendix A: Agreement of Compromise, Settlement and Release between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171742 to GCOR-171747	F.R.E. 401-402, 408	
336	NZ	11/16/94	Appendix B: Confidentiality Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171748 to GCOR-171750	F.R.E. 401-402, 408	
337	NZ		Summary of Novo Agreements	GCOR-171751	F.R.E. 401-402, 408	
338	NZ	3/23/98	Schedule 1.2	GCOR-171752 to GCOR-171753	F.R.E. 401-402, 408	
339	NZ	2/15/95	Filamentous Fungi License Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171754 to GCOR-171767	Stipulated	

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
340	NZ	2/13/95	Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171768 to GCOR-171772		F.R.E. 401-402, 408
341	NZ		Transaction Summary – GCI / Novo Cross-License	GCOR-171773		Stipulated
342	NZ	2/15/95	<i>Trichoderma</i> License Agreement between Novo Nordisk A/S and Genencor International, Inc.	GCOR-171774 to GCOR-171784		Stipulated
343	NZ	1/13/04	List of Genencor patent applications and granted patents	GCOR-171785 to GCOR- 171789		Stipulated
344	NZ/GCOR	4/12/06	License Agreement between The Procter & Gamble Company and Genencor International, Inc.	GCOR-171790 to GCOR- 171806	Exh. 9 to the Julie L. Davis Deposition	Stipulated
345	NZ/GCOR	4/12/06	(for detergent compositions comprising proteases and improved amylases)			
				GCOR-171807 to GCOR- 171820	Exh. 10 to the Julie L. Davis Deposition	Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION NO.	SOURCE(S)	OBJECTION(S)
346	NZ/GCOR	6/10/04	Patent License Agreement between The Procter & Gamble Company and Genencor International, Inc.	GCOR-171821 to GCOR- 171829	Exh. 11 to the Julie L. Davis Deposition	Stipulated
347	NZ/GCOR	11/10/03	License Agreement between The Procter & Gamble Company and Genencor International, Inc.	GCOR-171830 to GCOR- 171846	Part of Exh. 12 to the Davis Deposition (GCOR171830-171864)	Stipulated
348	NZ/GCOR	3/18/05	Patent License Agreement between The Procter & Gamble Company and Genencor International, Inc.	GCOR-171847 to GCOR- 171864	Part of Exh. 12 to the Davis Deposition (GCOR171830-171864)	Stipulated
349	NZ	11/5/04	Gluconic Acid License Agreement between Genencor International, Inc. and DSM research B.V.	GCOR-171865 to GCOR- 171878		Stipulated
350	NZ	10/12/04	Fungal Lactase License Agreement	GCOR-171879 to GCOR- 171888		Stipulated
351	NZ	11/1/02	License Agreement between Genencor International, Inc. and ChemGen Corp.	GCOR-171889 to GCOR- 171904		Stipulated

T.E. #.	OFFERED By	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
352	NZ	1/10/02	Phytase License Agreement	NV-D-0175429 to NV-D-0175436	Exh. 5 to the Julie L. Davis Deposition	Stipulated
353	NZ/GCOR	6/24/05	Fuel Ethanol Business Analysis	NV- 0015305 to NV- 0015335	LeFebvre Deposition Exhibit No. 39; Exh. 514 to the Jeff Faller Deposition; Document cited in David Teece Report	Stipulated
354	NZ	5/18/04	Spezyme Ethyl Commercial Case Review	GCOR-007225 to GCOR-007227		Stipulated
355	NZ	5/25/04	Spezyme Ethyl Amylase Sales Presentation	GCOR-011312 to GCOR-011401		Stipulated
356	NZ		Bid for RPPG Enzyme Business for 1 July 2005 to 30 June 2006	NV- 0000797 to NV- 0000801		Stipulated
357	NZ		Customer Sales Information	NV- 0112350 to NV- 0112375		F.R.E. 801-802

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
358	NZ		http://www.answers.com/topic/novo-nordisk			F.R.E.401-402, 801-802
359	NZ	8/18/06	Expert Report of David J. Teece			Stipulated
360	NZ/GCOR	8/18/06	List of Materials Reviewed		Attachment 3 to Teece Report	Stipulated
361	NZ/GCOR	8/18/06	Base Corrections to Ms. Davis Lost Profits Model		Teece Report Exhibit No. 1	Stipulated
362	NZ/GCOR	8/18/06	Spezyme Ethyl Replacement for Fuel ethanol Segment (Not Starch)		Teece Report Exhibit No. 2	Stipulated
363	NZ/GCOR	8/18/06	Spezyme Ethyl, Spezyme Fred, and Liquozyme SC Sales (KG)		Teece Report Exhibit No. 3	Stipulated
364	NZ/GCOR	8/18/06	Ms. Davis' Lost Profits Model Assuming Alternate But-For Sales Shares		Teece Report Exhibit No. 4	Stipulated
365	NZ/GCOR	8/18/06	Actual and But-For Price Comparisons		Teece Report Exhibit No. 5	Stipulated
366	NZ/GCOR	8/18/06	Liquozyme SC and Spezyme Ethyl Total Costs and Margins		Teece Report Exhibit No. 6	Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
367	NZ/GCOR	8/18/06	Spezyme Ethyl's Distribution Costs		Teece Report Exhibit No. 7	Stipulated
368	NZ/GCOR	8/18/06	Ms. Davis' Lost Profit Model Assuming Alternate But-For Profit Margins		Teece Report Exhibit No. 8	Stipulated
369	NZ/GCOR	8/18/06	Liquozyme SC Actual Average Prices		Teece Report Exhibit No. 9	Stipulated
370	NZ/GCOR	8/18/06	Ms. Davis' Lost Profits Model Assuming Various Price Elasticities of Demand		Teece Report Exhibit No. 10A	Stipulated
371	NZ/GCOR	8/18/06	Percent Change in Price: Liquozyme SC But-For Average Price vs. Spezyme Ethyl Actual Average Price		Teece Report Exhibit No. 10B	Stipulated
372	NZ/GCOR	8/18/06	But-For Sales Assuming Various Price Elasticities of Demand		Teece Report Exhibit No. 10C	Stipulated
373	NZ/GCOR	8/18/06	Ms. Davis' Price Erosion Model Assuming Various Price Elasticities of Demand		Teece Report Exhibit No. 11A	Stipulated
374	NZ/GCOR	8/18/06	Price Erosion Damages Assuming Various Price Elasticities of Demand		Teece Report Exhibit No. 11B	Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
375	NZ/GCOR	8/18/06	Adjusted But-For Sales (In Units) Assuming Various Price Elasticities of Demand		Teece Report Exhibit No. 11C	Stipulated
376	NZ/GCOR	8/18/06	Percent Change in But-For-Sales Assuming Various Price Elasticities of Demand		Teece Report Exhibit No. 11D	Stipulated
377	NZ	8/16/06	Standard Margin Extract 2006-May through July Spezyme Ethyl.xls			Stipulated
378	NZ	6/29/06	GLOSSARY_Contribution Margin Extract 2004-2006 Spezyme Ethyl.xls			Stipulated
379	NZ	6/26/06	Contribution Margin Extract 2004-2006 Spezyme Ethyl.xls			Stipulated
380	NZ	6/26/06	Freight As Revenue Spezyme Ethyl.xls			Stipulated
381	NZ	6/26/06	Standard Margin Extract 2000-2003 Spezyme Ethyl.xls			Stipulated
382	NZ/GCOR	6/29/06	Ethanol US Historical Sales_Cost_Profit v4.xls			Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
383	NZ/GCOR	6/29/06	Ethanol US Historical Sales_Cost_Profit v5.xls			Stipulated
384	NZ/GCOR	8/21/06	Trial Balance_2005_June 2006.xls			Stipulated
385	NZ/GCOR	8/21/06	Trial Balance_2004_2005.xls			Stipulated
386	NZ		NZ Customer Survey	NV-D-0174652 to NV-D-0174659		F.R.E. 801-802
387	NZ/GCOR		Transport Services - Freight Rates Eff. 8/1/06	NV-D-0175114 to NV-D-0175115		Stipulated
388	NZ/GCOR		Standard Balance by Account Group	NV-D-0175116 to NV-D-0175119		Stipulated
389	NZ/GCOR		Quarterly Royalties Chart	NV-D-0175112 to NV-D-0175113		Stipulated

390	NZ	Novozymes' world wide fermentation capacity outlook in April of 2005 (chart)	NV-D-0175477 to NV-D-0175479	F.R.E. 801-802; F.R.C.P. 26; Court's Scheduling Order; Mooted by Stipulation
391	NZ	Plant Diagram Charts	NV-D-0175484 to NV-D-0175485	F.R.E. 801-802; Mooted by Stipulation
392	NZ	10/2/01 U.S. Patent No. 6,297,038 for Amylase Variants		Stipulated
393	NZ	12/4/01 Novozymes A/S v Enzyme Bio-Systems LTD <i>et al</i> , Civ. Action No. 01-804 (D. Del.): Complaint For patent Infringement		F.R.E. 401-402, 801-802
394	NZ	1/4/02 Novozymes A/S v Enzyme Bio-Systems LTD <i>et al</i> , Civ. Action No. 01-804 (D. Del.): Memorandum of Law in Support of Plaintiff's Motion for Preliminary Injunction		F.R.E. 401-402, 801-802
395	NZ	1/4/02 Novozymes A/S v Enzyme Bio-Systems LTD <i>et al</i> , Civ. Action No. 01-804 (D. Del.): Appendix to Memorandum of Law in Support of Plaintiff's Motion for Preliminary Injunction		F.R.E. 401-402, 801-802

396	NZ	1/4/02	Novozymes A/S v Enzyme Bio-Systems LTD <i>et al.</i> , Civ. Action No. 01-804 (D. Del.): Plaintiff's Motion for Preliminary Injunction		F.R.E. 401-402, 801-802
397	NZ	8/25/06	Index to Documents Received after July 21, 2006 and Considered in Forming Opinion	Exhibit 2 to Supplemental Report of Julie L. Davis	Stipulated
398	NZ	8/25/06	Calculation of Lost Profits and Reasonable Royalty Damages	Exhibit 4A to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 702, 801-802
399	NZ	8/25/06	Calculation of Prejudgment Interest on Lost Profits and Reasonable Royalty Damages	Exhibit 4A1 to Supplemental Report of Julie L. Davis	F.R.E. 401-402,702, 801-802
400	NZ	8/25/06	Summary of Lost Profits Calculation	Exhibit 4B to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 702, 801-802
401	NZ	8/25/06	2005 Lost Profits Calculation	Exhibit 4B1 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 702, 801-802

402	NZ	8/25/06	2006 Lost Profits Calculation	Exhibit 4B2 to Supplemental Report of Julie L. Davis	F.R.E., 401-402, 702, 801-802
403	NZ	8/25/06	Reasonable Royalty Calculation of Infringing Sales Made Outside the U.S. Fuel Ethanol Industry	Exhibit 4C to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 702, 801-802
404	NZ	8/25/06	Royalty Base Calculation on Infringing Sales Made Outside the U.S. Fuel Ethanol Industry	Exhibit 4C1 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 702, 801-802
405	NZ	8/25/06	Infringing Sales Made Outside the U.S. Fuel Ethanol Industry 2005	Exhibit 4C2 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
406	NZ	8/25/06	Infringing Sales Made Outside the U.S. Fuel Ethanol Industry 2006	Exhibit 4C3 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
407	NZ	8/25/06	Calculation of Price Erosion Damages	Exhibit 5A to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802

408	NZ	8/25/06	Calculation of Prejudgment Interest on Price Erosion Damages	Exhibit 5A1 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
409	NZ	8/25/06	Calculation of Price Erosion Damages on Novozymes' Products	Exhibit 5B to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
410	NZ	8/25/06	Calculation of Price Erosion Damages on Novozymes' Products by Month	Exhibit 5C to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
411	NZ	8/25/06	Novozymes' Quantity Sold by Product	Exhibit 5D to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
412	NZ	8/25/06	Difference in Average Selling Price per Month	Exhibit 5E to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
413	NZ	8/25/06	Novozymes' Average Selling Price Per Product	Exhibit 5F to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802

414	NZ	8/25/06	Prime Interest Rates	Exhibit 6 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
415	NZ	8/25/06	Calculation of Reasonable Royalty Damages Assuming No Lost Profits	Exhibit 8A to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
416	NZ	8/25/06	Calculation of Prejudgment Interest on Reasonable Royalty Damages Assuming No Lost Profits	Exhibit 8A1 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
417	NZ	8/25/06	Reasonable Royalty Damages on Spezyme Ethyl Sold to the U.S. Fuel Ethanol Industry	Exhibit 8B to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
418	NZ	8/25/06	Reasonable Royalty Base Calculation Assuming No Lost Profits	Exhibit 8B1 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
419	NZ	8/25/06	Infringing Sales Made in the U.S. Fuel Ethanol Industry 2005	Exhibit 8B2 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802

420	NZ	8/25/06	Infringing Sales Made in the U.S. Fuel Ethanol Industry 2006	Exhibit 8B3 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
421	NZ	8/25/06	Reasonable Royalty Calculation on Infringing Sales Made Outside the U.S. Fuel Ethanol Market	Exhibit 8C to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
422	NZ	8/25/06	Royalty Base Calculation on Infringing Sales Made Outside the U.S. Fuel Ethanol Market	Exhibit 8C1 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
422A	NZ	8/25/06	Infringing Sales Made Outside the U.S. Fuel Ethanol Industry 2005	Exhibit 8C2 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
423	NZ	8/25/06	Infringing Sales Made Outside the U.S. Fuel Ethanol Industry 2006	Exhibit 8C3 to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802
424	NZ	8/25/06	Genencor Six Month Margin Analysis of Spezyme Fred and Spezyme Ethyl	Exhibit 8D to Supplemental Report of Julie L. Davis	F.R.E. 401-402, 701, 801-802

425	NZ		Novozymes Enzyme Supply Agreements	NV-D-0174041 to NV-D-0174539	F.R.C.P. 26; Scheduling Order
426			Space Reserved		
427			Space Reserved		Intentionally Left Open
428	NZ	6/13/06	EDC/Genencor email, Subject: Re: EDC-032371 Albert City		Stipulated
429	NZ	6/8/06	EDC/Genencor email, Subject: CR EDC-032385 Golden Grain Energy		Stipulated
430	NZ	6/6/06	EDC Call Report -- Golden Grain Energy, GC100 Trial	EDC-032634 to EDC-032636	Stipulated
431	NZ	2/1/06	Internal Genencor email, Subject: Ethyl 4 (GC 100) Meeting Update	GCOR-388727 to GCOR-388729	Stipulated
432	NZ	4/3/06	Customer email to EDC, Subject: Re: EDC-036541 GC100 Alpha Amylase		Stipulated
433	NZ	6/2/06	EDC/Genencor email, Subject: Fw: Plant Trial of GC 100	EDC-032701 to EDC-032703	Stipulated

434	NZ	3/27/06	Internal Genencor email, Subject: Fw: GC 100	GCOR-389787 to GCOR-389790	Stipulated
435	NZ	4/19/06	Internal Genencor email, Subject: GC 100 Supply Transition Plan	GCOR-389858	Stipulated
436	NZ	4/19/06	Internal Genencor email, Subject: Re: GC 100 Supply Transition Plan	GCOR-456369 to GCOR-456370	Stipulated
437	NZ	5/26/06	Internal Genencor email, Subject: Re: Info Needed	GCOR-456399 to GCOR-456402	Stipulated
438	NZ		RPMG Enzyme Supply Proposal July 1, 2006 to June 30, 2007	GCOR-456414	Stipulated
439	NZ	4/13/06	Internal Genencor email, Subject: Ethyl 3 and GC 100	GCOR-465926 to GCOR-465927	Stipulated
440	NZ	5/25/06	Internal Genencor email, Subject: GC100 as a product	GCOR-465949 to GCOR-465955	Stipulated
441			Space Reserved		
442	NZ		GC 100 Trial Summary	GCOR-471193 to GCOR-471198	Stipulated
443	NZ	5/18/06	Internal Genencor email, Subject: GC 100 Sales	GCOR-471211 to GCOR-471212	Stipulated

444	NZ	6/8/06	EDC/Genencor email, Subject: Golden Grain Info	EDC-031953 to EDC-031954	Stipulated
445	NZ	6/6/06	EDC/Genencor email, Subject: Hypothesis on thew slower fermentors	EDC-032374	Stipulated
446	NZ		Space Reserved		
447	NZ	2/1/06	Internal Genencor email, Subject: NZ	GCOR-388730	Stipulated
448	NZ		Fourth Quarter Highlights Innovation	GCOR-390484 to GCOR-390493	Stipulated
449	NZ	5/23/06	Internal Genencor email, Subject: Spezyme ethyl	GCOR-456394 to GCOR-456398	Stipulated
450	NZ	6/12/06	Internal Genencor email, Subject: RPMG amylase comparison	GCOR-456412 to GCOR-456413	Stipulated
451	NZ	4/17/06	Internal Genencor email, Subject: alpha amylase comparison	GCOR-389804	Stipulated
452	NZ		June 2005 Monthly Report	GCOR-337742 to GCOR-337744	Stipulated
453	NZ	3/14/06	EDC Call Report (US Energy Partners -- Russell, KS)	EDC-030821	Stipulated

454	NZ	4/14/06	Internal Genencor email, Subject: Panda Notes	GCOR-469740		Stipulated
455	NZ/GCOR	2003	Advance Pricing Agreement	NV-D-174798 to NV-D-175111		Stipulated
456	NZ		2005 Novozymes Annual Report	NV-D-174540 to NV-D-174648		F.R.E. 801-802
457	NZ	8/25/06	Genencor Int'l, Inc.'s Responses to Plaintiff Novozymes A/S' Fourth Set of Interrogatories			Stipulated
458	NZ	8/1/06	Genencor Int'l, Inc.'s Responses to Plaintiff Novozymes A/S' Third Set of Interrogatories			Stipulated
459	NZ	8/1/06	Defendant Enzyme Development Corporation's Responses to Plaintiff Novozymes A/S' Third Set of Interrogatories			Stipulated
460	NZ	7/17/06	Defendant Enzyme Development Corporation's Responses to Plaintiff Novozymes A/S' Second Set of Interrogatories			Stipulated
461	NZ	7/17/06	Genencor Int'l, Inc.'s Responses to Plaintiff Novozymes A/S' Second Set of Interrogatories			Stipulated

462	NZ/GCOR	8/25/06	Standard Margin Extract 2006-May thru August Spezyme Xtra-HPA-Alpha.xls		8/25/06 Email from J. Froyd to A. Lundgren, S. Woodley, D. Tellekson, R. Sullivan, and G. Hykal	Stipulated
463	NZ	9/13/06	Enzyme Development Corporation Inventory Sales History Report	EDC-041125 to EDC-041141	9/14/06 Email from J. Froyd to D. Tellekson, R. Sullivan, and G. Hykal	Stipulated
464	NZ/GCOR	8/25/06	Contribution Margin Extract 2004-2006 Spezyme Xtra-HPA-Alpha.xls		8/25/06 Email from J. Froyd to A. Lundgren, S. Woodley, D. Tellekson, R. Sullivan, and G. Hykal	Stipulated
465	NZ	6/9/06	Enzyme Development Corporation Inventory Sales History Report	EDC-011304 to EDC-011328		Stipulated
466	NZ		Enzyme Development Corporation Inventory Sales Analysis	EDC-011329 to EDC-011334		Stipulated
467	NZ	1/9/06	Enzyme Development Corporation Inventory Sales Analysis	EDC-011335 to EDC-011339		Stipulated

468	NZ	1/7/05	Enzyme Development Inventory Sales Analysis	Corporation	EDC-011340 to EDC-011344		Stipulated
469	NZ	1/5/04	Enzyme Development Inventory Sales Analysis	Corporation	EDC-011345 to EDC-011348		Stipulated
470	NZ	1/3/03	Enzyme Development Inventory Sales Analysis	Corporation	EDC-011349 to EDC-011350		Stipulated
471	NZ	6/2004	Spezyme Ethyl Product Information		EDC-005363 to EDC-005364		Stipulated
472	NZ	6/7/05	Inventory Sales History Report		EDC006464 to EDC006471		Stipulated
473	NZ	7/21/06	Expert Report and Disclosure of Julie L. Davis				F.R.E. 401-402, 701-702, 801- 802
474	NZ	8/25/06	Supplemental Disclosure of Julie L. Davis	Expert Report and	EDC-031734		F.R.E. 401-402, 701-702, 801- 802
475	NZ	8/24/06	Ethanol US Volumes.xls				Stipulated

476	NZ (proffered only for Spezyme® Ethyl Data)	10/5/06	Enzyme Sales History Report	Development Corp. Inventory	EDC-041142 to EDC-041162	Stipulated
477	NZ	10/5/06	Standard Margin Extract 2006-May thru September Spezyme Ethyl.xls			Stipulated
478	NZ	10/4/06	Ethanol US Historical Sales_Costs_Profit YTD Oct. 2006.xls			Stipulated
479	NZ	10/4/06	Ethanol US Historical Sales_Volumes YTD Oct. 2006.xls			Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
TE501	File History of U.S. Application No. 09/354,191, filed July 15, 1999	Genencor/EDC			Stipulated
TE502	File History of U.S. Application No. 08/600,656, filed February 13, 1996	Genencor/EDC			Stipulated
TE503	File History of U.S. Application No. 09/902,188, filed July 10, 2001	Genencor/EDC			Stipulated
TE504	PCT Publication No. WO 96/23873, entitled Amylase Variants, by Bisgaard-Frantzen et al., published August 8, 1996	Genencor/EDC			Stipulated
TE505	Declaration of Christian Isak Jorgensen, dated June 16, 2005 (with exhibits)	Genencor/EDC	C. Jorgensen Deposition Exh. 1; Exh. F to Memorandum of Law i/s/o Plaintiff's Motion		Stipulated
TE506	Email dated August 3, 2005 from A. Vikso-Nielsen to C. Sonksen et al., re: spezyme ethyl GCI characterization	Genencor/EDC	C. Jorgensen Deposition Exh. 3	NV-0070872	Stipulated
TE507	Email dated May 24, 2005 from D. Boyce to T. Burns et al., re Com Plus - Visit To Customer - 5/24/2005	Genencor/EDC	LeFebvre Deposition Exh. 27; Exh. O to Defendant's Opposition (APP. 1735 - 1737)	NV-0053244 - NV-0053246	Objection: FRE 801-802 (Hearsay)
TE508	Declaration of Torben V. Borchert, dated September 7, 2004	Genencor/EDC	Arnold Deposition Exh. 43; Exh. H to the Memorandum of Law i/s/o	NV-0154096 - NV-0154113	Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
			Plaintiffs Motion; Exh. I to Defendant's Opposition (APP. 1426-1443); Exh. C to the Machius Expert Report; Exh. C to the Klibanov Report; Exh. 5 to the Arnold Rebuttal Report	NV-0154314	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE509	<i>A Truncated, thermostable Bacillus stearothermophilus alpha amylase (1987)</i>	Genencor/EDC	Arnold Deposition Exh. 45	NV-0154314	
TE510	United States Patent Application Publication No. US 2003/0228673 A1, dated December 11, 2003	Genencor/EDC	Arnold Deposition Exh. 47	NV-0026897 - NV-0026924	Stipulated
TE511	Declaration of Frances H. Arnold in Novozymes A/S v. Enzyme Bio-Systems Ltd. et al., dated January 4, 2002	Genencor/EDC	Arnold Deposition Exh. 48	NV-0026897 - NV-0026924	Stipulated
TE512	Preliminary Amendment re Bisgaard- Frantzen Application, dated December 19, 2001.	Genencor/EDC	Borchert Deposition Exh. 51A; Exh. H to Defendant's	NV-0026897 - NV-0026924	Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
TE513	Office Action Summary re Application no: 10/025,648, dated July 29, 2003.	Genencor/EDC	Opposition (APP. 935-940)		Stipulated
TE514	Amendment to Claims re application no: 10/025,648, dated September 7, 2004.	Genencor/EDC	Borchert Deposition Exh. 51B; Exh. H to Defendant's Opposition (APP. 941-951)		Stipulated
TE515	Office Action Summary re Application no: 10/025,648, dated April 6, 2004.	Genencor/EDC	Borchert Deposition Exh. 51C; Exh. H to Defendant's Opposition (APP. 952-956)		Stipulated
TE516	Email dated August 11, 2004 from T. Borchert to K. Brown et al., re Spezyme deletion area detected	Genencor/EDC	Borchert Deposition Exh. 51D; Exh. H to Defendant's Opposition (APP. 958-969)	NV-0105362	Stipulated
TE517	Examiner-Initiated Interview Summary re application no: 10/025,648	Genencor/EDC	Borchert Deposition Exh. 51E; Exh. H to Defendant's Opposition (APP. 970)		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
TE518	Amendment to Claims re application no: 10/025,648	Genencor/EDC	Defendant's Opposition (APP. 971-972)		Stipulated
TE519	Email from H. Bisgaard-Frantzen to A. Norgaard et al., re Spezyme Ethyl	Genencor/EDC	Borchert Deposition Exh. 51G; Exh. H to Defendant's Opposition (APP. 973-978)	NV-0104922	Stipulated
TE520	Foreign Patent Application No: PA 1995 00126, filed February 3, 1995.	Genencor/EDC	Borchert Deposition Exh. 53; Exh. H to Defendant's Opposition (APP. 986-1047)		Stipulated
TE521	Foreign Patent Application No: PA 1995 00336, filed March 29, 1995.	Genencor/EDC	Borchert Deposition Exh. 54; Exh. H to Defendant's Opposition (APP. 1048-1128)		Stipulated
TE522	Foreign Patent Application No: PA 1995 01097, filed September 29, 1995.	Genencor/EDC	Borchert Deposition Exh. 55;		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
TE523	Foreign Patent Application No: PA 1995 01121, filed October 6, 1995.	Genencor/EDC	Exh. H to Defendant's Opposition (APP. 1129-1215)		
TE524	Declaration of Torben V. Borchert - Patent Interference No. 105, 206(JTM)	Borchert Deposition Exh. 56; Exh. H to Defendant's Opposition (APP. 1216-1303)	Stipulated		
TE525	Deposition Transcript of the Deposition of Torben Borchert, Ph.D., dated September 27, 2004	Genencor/EDC	Borchert Deposition Exh. 58; Exh. H to Defendant's Opposition (APP. 1333-1413); Exh. 3 to Borchert Declaration	NV-0021407 - NV-0021435	Stipulated
TE526	SR1 Spezyme Ethyl SM Action Plan - Proposal, dated August 20 to November 30, 2004	Genencor/EDC	Garbell Deposition Exh. 64	NV-0004794 - NV-004796	Stipulated
TE527	Declaration of William R. Pearson, dated September 8, 2005 (with exhibits)	Genencor/EDC	Pearson Deposition Exh. 69; Exh. D to Defendant's Opposition (APP. 446-491)		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
TE528	Email dated October 25, 2005 from W.	Genencor/EDC	Pearson Deposition		Stipulated
TE529	Pearson to S. Wang re: Sequence		Exh. 70		
TE530	alignment by the Align Program.				
TE531	Declaration of Xiaoqiu Huang, dated	Genencor/EDC	Huang Deposition		Stipulated
TE532	September 8, 2005 (with exhibits)				
TE533	O. Salazar <i>et al.</i> , <i>Thermostabilization of</i>	Genencor/EDC	Second Arnold	Deposition Exh. 85	
	<i>a Cytochrome P450 Peroxygenase,</i>				
CHEMBIOCHEM, pp. 891 - 893.					

Exhibit	Description	Offered By	Source	Production No.	Objection
TE534	The File Fastall16c32.shar.Z for FASTA Version 1.6 as Downloaded from the URL: ftp.virginia.edu/pub/fasta/tmp/fastral6c32.shar.Z (On Compact Disk)	Genencor/EDC	Exh. 5 to the Alber Declaration (APP. 174)	Objection: FRE 801-802 (Hearsay)	
TE535	The File Fastall16c32.shar.Z for FASTA Version 1.6 as Downloaded from the URL: ftp.virginia.edu/pub/fasta/tmp/fastral6c32.shar.Z (On Compact Disk)	Genencor/EDC	Exh. 5A to the Alber Declaration (APP. 175)	Objection: FRE 801-802 (Hearsay)	
TE536	Executable ALIGN Program from FASTA version 1.6 (On Compact Disc)	Genencor/EDC	Exh. 5B to the Alber Declaration (APP. 176); Exh. 56 to the Second Alber Report	Objection: FRE 801-802 (Hearsay)	
TE537	Compact disk	Genencor/EDC	Exh. 7 to the Alber Declaration (APP.179)	Objection: FRE 801-802 (Hearsay)	
TE538	GAP (Huang) Source Cofe File gap.c available at ftp://cs.mtu.edu/pub/huang	Genencor/EDC	Exh. 7A to the Alber Declaration (APP. 180)	Objection: FRE 801-802 (Hearsay)	
TE539	Executable GAP (Huang) Program (on	Genencor/EDC	Exh. 7B to the	Stipulate to use as a	

Exhibit	Description	Offered By	Source	Production No.	Objection
	compact disk)		Alber Declaration (APP. 181); Exh. 59 to the Second Alber Report	demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.	
TE540	GAP (Huang) Alignment: SEQ ID No. 3 to spezyme Ethyl	Genencor/EDC	Exh. 8 to the Alber Declaration (APP. 182 - 184)	Objection: FRE 801-802 (Hearsay)	
TE541	Hypothetical Alpha-Amylase Amino Acid Sequence	Genencor/EDC	Exh. 9 to the Alber Declaration (APP. 185)	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.	
TE542	GAP (GCG) Alignment: SEQ ID No. 3 to Hypothetical alpha-amylase	Genencor/EDC	Exh. 10 to the Alber Declaration (APP. 186 - 187)	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.	
TE543	ATCC 31,195 Alpha-Amylase Variant Amid Acid Sequence	Genencor/EDC	Exh. 11 to the Alber Declaration (APP. 188)	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as	

Exhibit	Description	Offered By	Source	Production No.	Objection
TE544	GAP (GCG) Alignment: Spezyme Ethyl to ATCC 31,195 alpha-amylase Variant	Genencor/EDC	Exh. 12 to the Alber Declaration (APP. 189 -190)		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE545	Caenepel, S. et al., <i>The mouse kinase: Discovery and comparative genomics of all mouse protein kinases</i> , PROC NATL ACAD. SCI. USA 101, pp. 11707 - 11712 (2004).	Genencor/EDC	Exh. 13 to the Alber Declaration (APP-192-197); Exh. 29 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE546	Stedman, H. et al., <i>Myosin gene mutation correlates with anatomical changes in the human lineage</i> , NATURE, Vol. 428, pp. 415-418 (2004).	Genencor/EDC	Exh. 14 to the Alber Declaration (APP. 199-202); Exh. 30 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE547	Satoh, H. et al., <i>Evidence for Movement of the alpha-amylase Gene in Two Phylogenetically Distant <i>Bacillus stearothermophilus</i> Strains</i> , JOURNAL OF BACTERIOLOGY, Vol. 170 No. 3, pp. 1034-1040 (1998).	Genencor/EDC	Exh. 15 to the Alber Declaration (APP. 203 - 210); Exh. 31 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.

Exhibit	Description	Offered By	Source	Production No.	Objection
TE548	Janecek, S., <i>Sequence similarities and evolutionary relationships of microbial, plant and animal alpha-amylase</i> , EUROPEAN JOURNAL BIOCHEM, 224, pp. 519-524 (1994).	Genencor/EDC	Exh. 16 to the Alber Declaration (APP. 211 - 217); Exh. 32 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE549	Janecek, S. et al., <i>Domain Evolution in the alpha-amylase Family</i> , JOURNAL OF MOLECULAR EVOLUTION, 45, pp. 322 - 331 (1997).	Genencor/EDC	Exh. 17 to the Alber Declaration (APP. 218-228); Exh. 33 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE550	Dauter, Z. et al., <i>X-ray Structure of Novamyl, the Five-Domain "Maltogenic" alpha-amylase from <i>Bacillus stearothermophilus</i>: Maltose and Acarbose Complexes at 1.7 Å Resolution</i> , BIOCHEMISTRY, 38, pp. 8385 - 8392 (1999).	Genencor/EDC	Exh. 18 to the Alber Declaration (APP. 229-237); Exh. 34 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE551	Crick, F H C., <i>On the Genetic Code</i> , SCIENCE, NEW SERIES, Vol. 139, No. 3554, p. 461-464 (1963).	Genencor/EDC	Exh. 19 to the Alber Declaration (APP. 238-243); Exh. 35 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE552	Benzer, S., Champs, S. P., <i>A Change</i>	Genencor/EDC	Exh. 20 to the		Stipulate to use as a

Exhibit	Description	Offered By	Source	Production No.	Objection
	<i>from Nonsense to Sense in the Genetic Code</i> , PROC NATL ACAD. SCI. USA, Vol. 42, No. 7, pp. 1114-1121 (1962).		Alber Declaration (APP 244 - 253); Exh. 36 to the Second Alber Report		Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE553	J. H. Miller <i>et al.</i> , <i>Genetic Studies of the lac Repressor</i> , JOURNAL OF MOLECULAR BIOLOGY, Vol. 131, pp. 191-222 (1979).	Genencor/EDC	Exh. 21 to the Alber Declaration (APP. 254-290); Exh. 37 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE554	Miller, J. H., <i>Use of Nonsense Suppression to Generate Altered Proteins</i> , METHODS OF ENZYMOLOGY, Vol. 208, pp. 543 - 563 (1991).	Genencor/EDC	Exh. 22 to the Alber Declaration (APP. 291-311); Exh. 38 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE555	Poteete, A., Hardy, L., <i>MINIREVIEW: Genetic Analysis of Bacteriophage T4 Lysozyme Structure and Function</i> , JOURNAL OF BACTERIOLOGY, Vol. 176, No. 22, pp. 6783 - 6788 (1994).	Genencor/EDC	Exh. 23 to the Alber Declaration (APP.312 - 318); Exh. J to the Alber Report; Exh. 39 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE556	Platt, T. <i>et al.</i> , <i>Translational Restarts: AUG Reinitiation of a lac Repressor</i>	Genencor/EDC	Exh. 24 to the Alber Declaration		Stipulate to use as a demonstrative.

Exhibit	Description	Offered By	Source	Production No.	Objection
	<i>Fragment</i> , PROC NATL. ACAD. SCI. USA, Vol. 69, No. 4, pp. 897 - 901 (1972).		(APP.319 -324); Exh. 40 to the Second Alber Report		Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE557	Files, J. <i>et al.</i> , <i>Translational Reinitiation of lac Repressor Fragments at Three Internal Sites Early in the lac i gene of Escherichia coli</i> , PROC. NAT. ACAD. SCI. USA, Vol. 71, No. 3, pp. 667-670 (1974).	Genencor/EDC	Exh. 25 to the Alber Declaration (APP. 326-329); Exh. 41 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE558	Gene, Nagase, H., and Nakamura, Y., <i>Mutations of the APC (Adenomatous Polyposis Coli)</i> , HUMAN MUTATION, Vol. 2, pp. 425-434 (1993).	Genencor/EDC	Exh. 26 to the Alber Declaration (APP.331-340); Exh. 42 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE559	Dayhoff, M., <i>Protein Data Introduction, ATLAS OF PROTEIN SEQUENCE AND STRUCTURE</i> , D-1 -D-10 (1972).	Genencor/EDC	Exh. 27 to the Alber Declaration (APP. 341 - 353); Exh. 43 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE560	Linzen <i>et al.</i> , <i>The Structure of Arthropod Hemocyanins</i> , SCIENCE, Vol. 229, No. 4713, pp. 519 - 524 (1985).	Genencor/EDC	Exh. 28 to the Alber Declaration (APP. 356 - 361);		Stipulate to use as a demonstrative. Reserve right to

Exhibit	Description	Offered By	Source	Production No.	Objection
TE561	Byrant-Greenwood, G., Schwabe, C., <i>Human Relaxins: Chemistry and Biology</i> , ENDOCRINE REVIEWS, Vol. 15, No. 1, pp. 5 - 26 (1994).	Genencor/EDC	Exh. 29 to the Alber Declaration (APP. 362 -384); Exh. 45 to the Second Alber Report	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.	
TE562	Dickerson, R.E., Geis, I., <u>The Structure and Action of Proteins</u> , Harper & Row, New York. pp. 52-66 (1969).	Genencor/EDC	Exh. 30 to the Alber Declaration (APP. 385-401); Exh. 46 to the Second Alber Report	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.	
TE563	Sambrook, Fritsch and Maniatis, <u>Molecular Cloning: A Laboratory Manual</u> , 2nd ed., Cold Springs Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 5.73-5.77 (1989).	Genencor/EDC	Exh. 31 to the Alber Declaration (APP. 402 - 407)	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.	
TE564	Astromoff, AN., Ptashne, M., <i>A Variant of lambda Repressor with an Altered Patterned of Cooperative Binding to DNA Sites</i> , PROC NATL. ACAD. SCI.	Genencor/EDC	Exh. 32 to the Alber Declaration (APP. 408-414); Exh. 48 to the	Stipulate to use as a demonstrative. Reserve right to object under FRE	

Exhibit	Description	Offered By	Source	Production No.	Objection
	USA, Vol. 92, No. 19, pp. 8110-8114 (1995).		Second Alber Report		801-802 (Hearsay) if offered as evidence.
TE565	Nye, J. <i>et al.</i> , <i>Interaction of Murine Ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif</i> , GENES & DEVELOPMENT, Vol. 6, pp. 975 - 990 (1992).	Genencor/EDC	Exh. 33 to the Alber Declaration (APP. 415-430); Exh. 49 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE566	Glumoff, T. <i>et al.</i> , <i>A Truncated, Thermostable Bacillus stearothermophilus alpha-amylase</i> , PROTEIN ENGINEERING, p. 241 (1987).	Genencor/EDC	Exh. 34 to the Alber Declaration (APP. 431-432); Exh. 50 to the Second Alber Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE567	M. Vihinen <i>et al.</i> , <i>C-Terminal truncations of a Thermostable Bacillus Stearothermophilus alpha amylase</i> , PROTEIN ENGINEERING, Vol. 7, No. 10, pp. 1255 - 1259 (1994).	Genencor/EDC	Exh. 35 to the Alber Declaration (APP. 433-438); Arnold Deposition Exh. 46; Second Alber Deposition Exh. 202; Exh. AQ to the Alber Report; Exh. 24 to the Second Alber Report	NV-0154302 - NV-0154306	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE568	Nakajima, R. <i>et al.</i> , <i>Nucleotide Sequence</i>	Genencor/EDC	Exh. 36 to the		Stipulate to use as a